The Manufacturers Life Insurance Company Has $24.29 Million Stock Position in Insmed, Inc. $INSM

Key Points

• The Manufacturers Life Insurance Company increased its stake in Insmed, Inc. by acquiring an additional 5,211 shares, bringing its total holdings to 318,392 shares valued at approximately $24.29 million.
• Analysts are generally optimistic about Insmed, with target price increases from multiple firms, raising it to as high as $142, leading to an average rating of "Moderate Buy" and a consensus target price of $132.57.
• Insmed reported quarterly earnings of ($1.70) per share, falling short of estimates, but its revenue of $107.42 million showed an 18.9% increase compared to the previous year.

The Manufacturers Life Insurance Company lifted its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 1.7% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 318,392 shares of the biopharmaceutical company's stock after buying an additional 5,211 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.18% of Insmed worth $24,290,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of INSM. M&T Bank Corp raised its position in shares of Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock valued at $252,000 after buying an additional 147 shares in the last quarter. Snowden Capital Advisors LLC grew its position in Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after buying an additional 158 shares in the last quarter. Cullen Frost Bankers Inc. increased its stake in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Insmed by 6.5% in the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock worth $287,000 after purchasing an additional 228 shares during the period. Finally, Parkman Healthcare Partners LLC increased its holdings in Insmed by 0.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock valued at $2,463,000 after buying an additional 235 shares during the period.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 24,272 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the completion of the sale, the insider owned 54,902 shares of the company's stock, valued at $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Roger Adsett sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the sale, the chief operating officer directly owned 105,637 shares of the company's stock, valued at $13,477,168.46. This represents a 19.14% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 535,320 shares of company stock valued at $54,581,793 over the last ninety days. Insiders own 3.00% of the company's stock.

Wall Street Analyst Weigh In

INSM has been the topic of several recent analyst reports. Morgan Stanley raised their target price on shares of Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. UBS Group raised their target price on shares of Insmed from $124.00 to $133.00 and gave the company a "buy" rating in a report on Friday, August 8th. Mizuho raised their target price on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a report on Wednesday, August 13th. William Blair assumed coverage on shares of Insmed in a research note on Wednesday, August 20th. They issued an "outperform" rating on the stock. Finally, Citigroup raised shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $139.86.

Insmed Trading Up 0.5%

NASDAQ INSM traded up $0.75 during mid-day trading on Monday, reaching $145.85. 270,723 shares of the stock were exchanged, compared to its average volume of 2,788,339. The stock has a market cap of $30.83 billion, a P/E ratio of -25.54 and a beta of 0.96. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock has a 50 day simple moving average of $114.64 and a 200-day simple moving average of $89.74. Insmed, Inc. has a one year low of $60.40 and a one year high of $146.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same period in the prior year, the business earned ($1.94) EPS. The company's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. On average, analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.